Treatment of chronic hepatitis delta virus (Hdv) infection with human lymphoblastoid alpha interferon

  • P. Farci
  • , P. Karayiannis
  • , M. G. Brook
  • , A. Smedile
  • , M. E. Lai
  • , A. Balestrieri
  • , J. A. Saldanha
  • , J. Monjardino
  • , J. Gerin
  • , H. C. Thomas

Research output: Contribution to journalArticlepeer-review

Abstract

Ten patients with evidence of continuing HDV replication were treated with lymphoblastoid alpha-interferon and eight more were followed as a non-randomized control group. Four out of eight patients who completed one year of follow-up had cleared HDV-RNA from the serum whilst none of the control group did so. In these four responding cases there was a transient increase in transaminase levels during treatment and in two, this was followed by improvement. One patient also cleared HBV and seroconverted to anti-HBs (antibody to hepatitis B surface antigen - HBsAg). In one patient with sustained loss of HDV, recurrence of HDV infection was detected 18 months after completion of treatment.These data suggest that alpha-interferon can inhibit HDV replication in the short term but relapse after one to two years may occur. Inhibition of HDV-RNA is associated with improvement in the inflammatory liver disease and now larger studies are required to determine whether it influences survival.

Original languageEnglish
Pages (from-to)1045-1054
Number of pages10
JournalQJM
Volume73
Issue number2
DOIs
Publication statusPublished - 1989

Fingerprint

Dive into the research topics of 'Treatment of chronic hepatitis delta virus (Hdv) infection with human lymphoblastoid alpha interferon'. Together they form a unique fingerprint.

Cite this